Orthogon Therapeutics Raises an Additional $11M Financing for Its BK Virus Antiviral Drug Program
Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications CANTON, Mass. — Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to $36 million. This financing supports the continued advancement of its first-in-class drug against BK polyomavirus. BK virus infections are a major […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.